TY - T1的孕期疾病活动Fingolimod撤军后由于计划怀孕的女性多发性硬化症(P5.032) JF -神经学乔-神经学六世- 90 - 15补充SP - P5.032盟Spalmai Hemat AU -玛丽亚Houtchens盟安吉拉Vidal-Jordana AU -迈克尔贵港市盟Doria首页na蓝迪AU - Miguel D 'Haeseleer盟Pietro Annovazzi AU - Mar Tintore盟桑德拉·泰尔AU -拉尔夫黄金盟Kerstin Hellwig Y1 - 2018/04/10 UR - //www.ez-admanager.com/content/90/15_Supplement/P5.032.abstract N2 -目的:确定复发和残疾女性怀孕的风险与多发性硬化症(MS)停止Fingolimod (FTY)怀孕计划和那些停止FTY曾经怀孕了。背景:FTY撤军后复发风险的大小在女士计划怀孕的女性是未知的,但严重的疾病活动。设计/方法:怀孕前瞻性收集的德国女士和怀孕的注册表和2017年9月由六个国际合作者。详细信息女士,怀孕、复发和怀孕的结果。结果:我们分析了139个妊娠分为A组:FTY停止在末次月经前2个月(LMP) (n = 35)(去年FTY和LMP之间的间隔中位数:328天(范围61 - 312))和B组(n = 104):暴露于FTY(平均暴露38岁,6天(1 - 123))从LMP。8怀孕仍在继续。35岁的女性在A组,10(28日6%)经历过复发怀孕。怀孕后,在A组13(37 1%)女性在三期16复发根据三个月(7-7-2)25(24%)的女性相比,B组(根据怀孕33总:9-14-10)。残疾的信息可用于32/38的女性(12(92年3%)A组和B组(80%)20日)怀孕期间复发:5组(14 3%)女性经历了eds恶化中值0.8 (0 - 2),7 (2 - 5);在B组12(11 5%)妇女经历了eds恶化中值1,95 (0 - 4)33 (2 - 4、5)。结果的差异没有统计学意义。结论:尽管怀孕的自然保护,一大群的女性在怀孕期间会经历复发残疾人积累的一些女性。披露:Hemat博士没有披露。 Dr. Houtchens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme Sanofi, Teva Neurosciences, Biogen, Genentech. Dr. Vidal-Jordana has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Roche, and Sanofi-Aventis. Dr. Guger has nothing to disclose. Dr. Landi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva. Dr. D'Haeseleer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva. Dr. Annovazzi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Merck Serono, Genzyme, Biogen and Teva. Dr. Tintoré has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Schering Pharma, Merck-Serono, Biogen-Idec, Teva Pharmaceuticals, Sanofi-Aventis, Novartis, Almirall, Genzyme, and Roche. Dr. Thiel has nothing to disclose. Dr. Gold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Diseases, Experimental Neurology and the Journal of Neuroimmunology. Dr. Gold has received research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis. Dr. Hellwig has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speaker honoraria: Biogen Idec, Teva, Sanofi Aventis, Novartis, Bayer Healthcare, Merck Serono. ER -